Matricelf is a pioneering biotechnology company based in Tel Aviv. They specialize in developing a platform for autologous tissue engineering, offering innovative solutions for a wide range of medical conditions. Established in 2019 by Professor Tal Dvir from the Laboratory of Tissue Engineering and Regenerative Medicine at Tel Aviv University, Matricelf is at the forefront of redefining autologous regenerative medicine.

Their team consists of experts and professionals who bring a wealth of experience and knowledge to the company. From the Board of Directors, including Chairman Doron Birger and renowned immunologist Prof. Ruth Arnon, to the Co-Founder and CSO Prof.

Tal Dvir, who has made significant contributions in the field of cardiac tissue engineering and regeneration. Matricelf's dedication to scientific excellence is evident through their Scientific Advisory Board, which includes experts like Dr. Eckhard von Keutz, Dr.

Nicholas Theodore, and Prof. Mark Tuszynski. These individuals contribute to the company's cutting-edge research and development efforts.

Overall, Matricelf is committed to revolutionizing regenerative medicine through their innovative platform and expertise, ultimately improving the lives of patients worldwide